At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Post-licensure Safety Surveillance Study of Menactra® Vaccine When Administered As a 2-dose Schedule to Children 9 Months Through 23 Months of Age.
In Brief
An observational study evaluating Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate for Meningitis and Meningococcal Infection. Completed, enrolled 116 participants across 1 site.
Detailed Summary
This is a passive-surveillance study that will accrue subjects for surveillance. For each accrued subject, surveillance for outcomes will continue for six months following the first dose. If a second dose is given within that time, then surveillance will be continued for six months following the second dose. Observational Objective: * To describe and characterize adverse events occurring after vaccination with Menactra vaccine.
Study Details
Timeline
Interventions
0.5 mL, Intramuscular